公募基金医药板块2024Q3持仓分析：2024Q3医药持仓持续回调，医疗器械仓位下滑

Investment Rating - The report indicates a continuous adjustment in the holdings of public funds in the pharmaceutical sector, with a current holding ratio of 9.66%, down by 0.22 percentage points from the previous quarter [5][13]. Core Insights - In Q3 2024, public funds have reduced their exposure to the pharmaceutical sector, with the highest historical holding ratio recorded at 18.23% in Q2 2020 [5][13]. - The secondary industry holdings within the pharmaceutical sector show significant declines in medical devices, biological products, and traditional Chinese medicine, while chemical pharmaceuticals and medical services have seen notable increases [5][21]. - The top ten pharmaceutical stocks by total market value held by public funds in Q3 2024 include: Heng Rui Pharmaceutical (37.37 billion), Mai Rui Medical (36.56 billion), WuXi AppTec (19.36 billion), and others, with significant increases in holdings for WuXi AppTec, Kanglong Chemical, and others [6][27]. Summary by Sections 1. Pharmaceutical Sector Holdings - Public funds' holdings in the pharmaceutical sector have decreased, with a current ratio of 9.66% [5][13]. - The breakdown of secondary industry holdings shows: Chemical Pharmaceuticals at 2.94% (+0.31pct), Medical Devices at 2.72% (-0.52pct), Medical Services at 1.99% (+0.47pct), Biological Products at 0.99% (-0.18pct), Traditional Chinese Medicine at 0.77% (-0.26pct), and Pharmaceutical Commerce at 0.24% (-0.04pct) [21][22]. 2. Individual Stock Analysis - The top ten pharmaceutical stocks by total market value held by public funds are: Heng Rui Pharmaceutical (37.37 billion), Mai Rui Medical (36.56 billion), WuXi AppTec (19.36 billion), and others [27][31]. - The stocks with the largest increases in holdings include Heng Rui Pharmaceutical (+11.34 billion), WuXi AppTec (+7.09 billion), and Ai Er Eye Hospital (+4.82 billion) [31][32]. - Conversely, the stocks with the largest decreases in holdings include Mai Rui Medical (-4.93 billion), Nuotai Biological (-1.70 billion), and Xingqi Eye Medicine (-1.67 billion) [31][32].